Clinical Trials Logo

Clinical Trial Details — Status: Not yet recruiting

Administrative data

NCT number NCT04377048
Other study ID # 202001045MIPA
Secondary ID
Status Not yet recruiting
Phase Phase 2
First received
Last updated
Start date July 1, 2020
Est. completion date December 31, 2022

Study information

Verified date May 2020
Source National Taiwan University Hospital
Contact Shu-Ling Wu
Phone +886-2-23123456
Email shulingwu.ntuh@gmail.com
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

This study assumes that to achieve significant therapeutic efficacy in advanced pancreatic cancer with immunotherapy, the immune system must remain relatively intact. Therefore, early use, low tumor load, adequate organ function, and slow growth of the tumor are the key points. Stage IV pancreatic adenocarcinoma patients with limited metastatic lesions and adequate organ function will be enrolled. Gemcitabine plus S-1 (GS) will be administered initially, and then CA 19-9 will be evaluated. Those fulfilling pre-defined criteria of CA 19-9 will receive nivolumab add-on therapy.


Recruitment information / eligibility

Status Not yet recruiting
Enrollment 38
Est. completion date December 31, 2022
Est. primary completion date July 1, 2022
Accepts healthy volunteers No
Gender All
Age group 20 Years to 75 Years
Eligibility Inclusion Criteria:

1. histologically proven pancreatic adenocarcinoma

2. newly diagnosed, stage IV pancreatic cancer with limited metastases and tumor burden

3. no previous radiotherapy, chemotherapy, targeted therapy, curative surgery, local therapy (eg. radiofrequency ablation, irreversible electroporation, etc.), immunotherapy, cell therapy (autologous or allogenic) used for pancreatic cancer

4. presence of at least one measurable lesion at the pancreas and at least one measurable metastatic lesion

5. age between 20 and 75 years at registration

6. ECOG performance status of 0 or 1

7. adequate major organ functions

8. baseline CA 19-9 > upper limit of normal

9. Glasgow prognostic score of 0 (ie. albumin = 3.5 g/dL and CRP = 1 mg/dL)

10. ability to take study medication (S-1) orally

11. no clinically significant abnormal ECG findings within 28 days prior to registration

12. Women of childbearing potential (including women with chemical menopause or no menstruation for other medical reasons) must agree to use contraception from the time of informed consent until 5 months or more after the last dose of investigational products. Also, women must agree not to breastfeed from the time of informed consent until 5 months or more after the last dose of the investigational product.

13. Men must agree to use contraception from the start of study treatment until 7 months or more after the last dose of the investigational product.

14. Sign written informed consent

Exclusion Criteria:

1. interstitial lung disease that is symptomatic or may interfere with the detection or management of suspected treatment-related pulmonary toxicity within 28 days prior to registration

2. presence of diarrhea = CTCAE v.5.0 grade 2

3. concomitant systemic infection requiring treatment

4. clinically significant co-morbid medical conditions, including cardiovascular disease known autoimmune disease

5. concurrent autoimmune disease or history of chronic or recurrent autoimmune disease

6. prior organ allograft or allogeneic bone marrow transplantation

7. received systemic corticosteroids (except for temporary use, e.g., for examination or prophylaxis of allergic reactions) or immunosuppressants within 28 days before registration

8. HBV (positive HBsAg or HBV DNA) or HCV carrier (positive anti-HCV or HCV RNA)

9. known history of testing positive for human immunodeficiency virus (HIV) or known acquired immunodeficiency syndrome

10. moderate or severe ascites, pleural effusion, or pericardial effusion requiring treatment

11. central nervous system metastasis

12. prior or concurrent malignancies within the last 3 years, with the exception of carcinoma in situ of the cervix, or basal type skin cancer

13. concomitant treatment with flucytosine, phenytoin or warfarin

14. any major surgery within 4 weeks of study treatment. Participants must have recovered from the effects of major surgery or significant traumatic injury at least 14 days before the first dose of study treatment.

15. transfusion from 72 hours prior to registration to the first dose of study drug administration

16. pregnant women or nursing mothers, or positive pregnancy tests

17. severe mental disorder

18. treatment with botanical preparations (eg, herbal supplements or traditional Chinese medicines) intended for general health support or to treat the disease under study within 2 weeks prior to registration

19. vaccine therapies for prevention of infectious diseases within 4 weeks of study drug administration except inactivated seasonal influenza vaccine

20. any condition requiring anti-platelet or anticoagulant therapy within 12 weeks prior to registration

21. oral or iv antibiotic use within 2 weeks prior to registration

22. uncontrollable pain caused by a tumor

23. receiving antineoplastic agents within 28 days before registration

24. patients judged by the principal investigator or subinvestigators to be inappropriate as subjects of this study

Study Design


Related Conditions & MeSH terms


Intervention

Drug:
Nivolumab
as described in "NGS Arm"
Gemcitabine
as described in "NGS Arm"
Tegafur-Gimeracil-Oteracil
as described in "NGS Arm"

Locations

Country Name City State
n/a

Sponsors (4)

Lead Sponsor Collaborator
National Taiwan University Hospital ACT Genomics, Ono Pharmaceutical Co. Ltd, TTY Biopharm

References & Publications (2)

Ueno H, Ioka T, Ikeda M, Ohkawa S, Yanagimoto H, Boku N, Fukutomi A, Sugimori K, Baba H, Yamao K, Shimamura T, Sho M, Kitano M, Cheng AL, Mizumoto K, Chen JS, Furuse J, Funakoshi A, Hatori T, Yamaguchi T, Egawa S, Sato A, Ohashi Y, Okusaka T, Tanaka M. Ra — View Citation

Weiss GJ, Blaydorn L, Beck J, Bornemann-Kolatzki K, Urnovitz H, Schütz E, Khemka V. Phase Ib/II study of gemcitabine, nab-paclitaxel, and pembrolizumab in metastatic pancreatic adenocarcinoma. Invest New Drugs. 2018 Feb;36(1):96-102. doi: 10.1007/s10637-0 — View Citation

Outcome

Type Measure Description Time frame Safety issue
Primary response rate overall response rate of gemcitabine/S-1/nivolumab 6 weeks
See also
  Status Clinical Trial Phase
Terminated NCT02495896 - Recombinant EphB4-HSA Fusion Protein With Standard Chemotherapy Regimens in Treating Patients With Advanced or Metastatic Solid Tumors Phase 1
Completed NCT02005315 - A Study of Vantictumab (OMP-18R5) in Combination With Nab-Paclitaxel and Gemcitabine in Previously Untreated Stage IV Pancreatic Cancer Phase 1
Completed NCT01453153 - Study of Gemcitabine + PEGPH20 vs Gemcitabine Alone in Stage IV Previously Untreated Pancreatic Cancer Phase 1/Phase 2
Completed NCT01064622 - Gemcitabine Hydrochloride With or Without Vismodegib in Treating Patients With Recurrent or Metastatic Pancreatic Cancer Phase 1/Phase 2
Completed NCT00095966 - Sorafenib and Gemcitabine in Treating Patients With Locally Advanced or Metastatic Pancreatic Cancer Phase 2
Completed NCT02178436 - Gemcitabine, Nab-paclitaxel and KPT-330 in Advanced Pancreatic Cancer Phase 1/Phase 2
Completed NCT01846520 - Family Caregiver Palliative Care Intervention in Supporting Caregivers of Patients With Stage II-IV Gastrointestinal, Gynecologic, Urologic and Lung Cancers N/A
Completed NCT01647828 - A Phase 1b/2 Study of OMP-59R5 (Tarextumab) in Combination With Nab-Paclitaxel and Gemcitabine in Subjects With Previously Untreated Stage IV Pancreatic Cancer Phase 1/Phase 2
Completed NCT01191684 - Vaccine Therapy in Treating Patients With Colorectal, Stomach, or Pancreatic Cancer Phase 1
Terminated NCT01555489 - Assessing the Efficacy and Safety of IV Vitamin C in Combination With Standard Chemotherapy for Pancreatic Ca Phase 2
Completed NCT01232829 - Gamma Secretase Inhibitor RO4929097 in Previously Treated Metastatic Pancreas Cancer Phase 2
Terminated NCT01233505 - Veliparib, Oxaliplatin, and Capecitabine in Treating Patients With Advanced Solid Tumors Phase 1
Completed NCT00735917 - Saracatinib in Treating Patients With Previously Treated Metastatic Pancreatic Cancer Phase 2
Completed NCT02896907 - Ascorbic Acid and Combination Chemotherapy in Treating Patients With Locally Advanced or Recurrent Pancreatic Cancer That Cannot Be Removed by Surgery Early Phase 1
Completed NCT02307539 - Palliative Care in Improving Quality of Life in Patients With Newly Diagnosed Pancreatic Cancer N/A
Completed NCT02050178 - Dose Escalation Study of OMP-54F28 in Combination With Nab-Paclitaxel and Gemcitabine in Patients With Previously Untreated Stage IV Pancreatic Cancer Phase 1
Completed NCT01488552 - Gemcitabine+Nab-paclitaxel and FOLFIRINOX and Molecular Profiling for Patients With Advanced Pancreatic Cancer Phase 1/Phase 2
Completed NCT01222689 - Selumetinib and Erlotinib Hydrochloride in Treating Patients With Locally Advanced or Metastatic Pancreatic Cancer Phase 2
Completed NCT00397787 - Sunitinib in Treating Patients With Metastatic Pancreatic Cancer That Progressed After First-Line Therapy With Gemcitabine Phase 2
Completed NCT00028496 - Vaccine Therapy With or Without Sargramostim in Treating Patients With Advanced or Metastatic Cancer Phase 1